Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: Abridged cochrane Systematic review and network meta-analysis

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Hazlewood, Glen S ^a,b,c,d   Barnabe, Cheryl ^a,b,d   Tomlinson, George ^e   Marshall, Deborah ^b,d   Devoe, Dan ^d   Bombardier, Claire ^e,f,g  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHLOROQUINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; BAYES THEOREM; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84964584679     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i1777     Document Type: Article

References (38)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509. doi: 10.1136/annrheumdis-2013-204573.
2. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheum 2016;68:1-26.
3. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28. doi:10.1016/j.jval.2011.04.002.
4. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848.
5. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010;4:CD008495.
6. O'Dell JR, Mikuls TR, Taylor TH, et al. CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18. doi:10.1056/NEJMoa1303006.
7. van Vollenhoven RF, Geborek P, Forslind K, et al. Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20. doi:10.1016/S0140-6736 (12) 60027-0.
8. Moreland LW, O'Dell JR, Paulus HE, et al. TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35. doi:10.1002/art.34498.
9. Hazlewood G, Barnabe C, Tomlinson G, Marshall D, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis (Protocol). Cochrane Database Syst Rev 2013;1:CD010227.
10. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8. doi:10.1136/ard.2010.138461.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. doi:10.1002/art.1780310302.
12. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
13. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35. doi:10.1002/art.1780380602.
14. Ory PA. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 2003;62:597-604. doi:10.1136/ard.62.7.597.
15. Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928.
16. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17. doi:10.1177/0272989X12458724.
17. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19. doi:10.2165/00019053-200624010-00001.
18. Jonas DE, Wilkins TM, Bangdiwala S, et al. Findings of Bayesian Mixed Treatment Comparison Meta-Analyses: Comparison and Exploration Using Real-World Trial Data and Simulation. Agency for Healthcare Research and Quality, 2013.
19. Brooks S, Gelman A. General Methods for Monitoring Convergence of Iterative Simulations. J Comput Graph Stat 1998;7:434-55.
20. Plummer M. rjags: Bayesian Graphical Models using MCMC. R package version 3-14. 2014. https://libraries.io/cran/rjags/3-14.
21. Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. doi:10.1136/bmj.g5630.
22. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44. doi:10.1002/sim.3767.
23. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005;24:2401-28. doi:10.1002/sim.2112.
24. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012;41:818-27. doi:10.1093/ije/dys041.
25. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 2015;68:52-60. doi:10.1016/j.jclinepi.2014.08.012.
26. van Vollenhoven RF, Fleischmann R, Cohen S, et al. ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19. doi:10.1056/NEJMoa1112072.
27. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94. doi:10.1136/annrheumdis-2013-203843.
28. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103. doi:10.1136/ard.2007.080002.
29. Cuomo G, Molinaro G, La Montagna G, Migliaresi S, Valentini G. [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens][Italian]. Reumatismo 2006;58:22-5.
30. Joo K, Heejung K, Lim MJ, Kwon SR, Park W. Safety and efficacy of TNFa inhibitor versus leflunomide in patients with rheumatoid arthritis inadequately responding to methotrexate in Korea. Int J Rheum Dis 2012;15:53-4.
31. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20. doi:10.1002/art.10190.
32. Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:510-5. doi:10.1136/annrheumdis-2013-204588.
33. Hawkins N, Scott DA, Woods B. How far do you go? Efficient searching for indirect evidence. Med Decis Making 2009;29:273-81. doi:10.1177/0272989X08330120.
34. Thorlund K, Druyts E, Aviña-Zubieta JA, Wu P, Mills EJ. Why the findings of published multiple treatment comparison metaanalyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 2013;72:1524-35. doi:10.1136/annrheumdis-2012-201574.
35. Graudal N, Hubeck-Graudal T, Tarp S, Christensen R, Jürgens G. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One 2014;9:e106408. doi:10.1371/journal.pone.0106408.
36. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63. doi:10.1002/art.27592.
37. Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005;44:1414-21. doi:10.1093/rheumatology/kei031.
38. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15. doi:10.1016/j.jclinepi.2010.07.017.